A Phase 3 Trial of Inhaled Mosliciguat in PH-ILD (PHrontier)
A Phase 3, Multicenter, Randomized, Double-Blind Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Mosliciguat in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease
研究概览
详细说明
This study is a randomized double-blind placebo control study with an extension.
The study consists of 2 periods: a blinded placebo-controlled period (24 weeks) and an extension (beyond 24 weeks).
Participants will be randomized to receive mosliciguat or placebo in the 24-week double-blind treatment period.
All participants who complete the 24-week double-blind period may continue to participate in the extension period where all participants receive mosliciguat.
研究类型
注册 (估计的)
阶段
- 第三阶段
联系人和位置
学习联系方式
- 姓名:Pulmovant Inc
- 电话号码:+1-919-462-1310
- 邮箱:clinicaltrials@pulmovant.com
学习地点
-
-
Florida
-
Kissimmee、Florida、美国、34746
- 招聘中
- Clinical Research Site
-
接触:
- Clinical Site
-
-
Kentucky
-
Louisville、Kentucky、美国、40202
- 招聘中
- Clinical Research Site
-
接触:
- Clinical Site
-
-
Oregon
-
Bend、Oregon、美国、97701
- 招聘中
- Clinical Research Site
-
接触:
- Clinical Site
-
-
参与标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
描述
Inclusion Criteria:
- Participants willing and able to provide informed consent.
Participants with diagnosis of pulmonary hypertension (PH) associated with interstitial lung disease (ILD). Diagnosis will be confirmed by a high-resolution computerized tomography (HR-CT) scan showing diffuse parenchymal disease. Eligible diagnosed disease include:
- Idiopathic interstitial pneumonia (IIP)
- Chronic Hypersensitivity pneumonitis
- ILD associated connective tissue disease (CTD)
- Confirmed pulmonary hypertension by right heart catheterization (RHC).
- Ability to perform 6-minute walk distance ≥100 meters.
Exclusion Criteria:
- Diagnosis of PH Group 1 (eg, pulmonary arterial hypertension), Group 2 (related to left heart disease), Group 4 (eg, chronic thromboembolic pulmonary hypertension), or Group 5 (eg, unclassified).
- Exacerbation of underlying lung disease requiring change in therapy or hospitalization within 28 days prior to randomization
- Receiving >10 L/min oxygen supplementation by any mode of delivery at rest
- History of intolerance to mosliciguat, or sGC stimulators or activators.
- Initiation of pulmonary rehabilitation or ongoing acute phase of rehabilitation within 28 days prior to randomization.
- Receipt of investigational or interventional therapy within 42 days OR 5 half-lives (whichever is longer) prior to randomization.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:四人间
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
有源比较器:莫斯利西瓜特
参与者将被随机分配每天接受吸入莫斯利西呱或安慰剂,持续 24 周
|
吸入剂量水平 1、2 或 3
Administration via dry powder inhaler
|
|
安慰剂比较:匹配的安慰剂
参与者将被随机分配每天接受吸入莫斯利西呱或安慰剂,持续 24 周
|
Administration via dry powder inhaler
Matching Placebo for inhalation
|
|
实验性的:扩大
第 24 周后,所有参与者都可以在延长期内接受 mosliciguat
|
吸入剂量水平 1、2 或 3
Administration via dry powder inhaler
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change from Baseline in 6-Minute Walk Distance (6MWD)
大体时间:Baseline to Week 24
|
The 6MWD measures the distance a participant is able to walk quickly on a flat, hard surface in a period of 6 minutes
|
Baseline to Week 24
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Time to Clinical Worsening (TTCW)
大体时间:From randomization through Week 24
|
Time from randomization to first occurrence of any of the following events as adjudicated by the independent Event Adjudication Committee (EAC).
|
From randomization through Week 24
|
|
Percent Change from Baseline in Pulmonary Vascular Resistance (PVR)
大体时间:Baseline to Week 24
|
PVR evaluated using right heart catheterization (RHC)
|
Baseline to Week 24
|
|
Change from Baseline in N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP)
大体时间:Baseline to Week 24
|
The NT-ProBNP serum concentrations is a useful biomarker associated with changes in right heart morphology and function.
NT-proBNP serum concentration will be assessed to compare the severity of heart failure at Baseline and Week 24.
|
Baseline to Week 24
|
|
Change from Baseline in Living with Pulmonary Fibrosis (L-PF) Total Symptom Score
大体时间:Baseline to Week 24
|
Change from baseline to Week 24 in L-PF total symptom scores (patient-reported outcome).
|
Baseline to Week 24
|
合作者和调查者
调查人员
- 研究主任:Ubaldo Martin、Pulmovant, Inc.
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.